StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) company profile

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)

Close on Nov 17, 2026Market cap $527.10MP/E –Yield –

About ArriVent BioPharma

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical company that identifies, develops, and commercializes differentiated cancer therapies, with a primary focus on solid tumors. Its lead product candidate is firmonertinib, an investigational tyrosine kinase inhibitor evaluated in clinical trials for non-small cell lung cancer characterized by epidermal growth factor receptor mutations, notably exon 20 insertions and PACC mutations. In addition, the firm is developing a pipeline of novel therapeutics, including next-generation antibody drug conjugates such as ARR-217 for gastrointestinal cancers and other solid tumors. Its prospective customers and end users are cancer patients with underserved oncological conditions.

The company operates globally through collaborative clinical development programs across regions including the United States, Europe, and Asia. It sources therapeutic candidates worldwide—frequently initiating partnerships in China—and conducts international multi-center clinical trials, with commercial rights spanning territories outside greater China. Its corporate headquarters is not stated in the provided text.

Summary of the business section of ArriVent BioPharma's latest annual report, written by StockData.

Company profile

Company

Legal name
ArriVent BioPharma, Inc.
Founded
2021
Headquarters
Newtown Square, PA
Address
18 Campus Blvd., Suite 100 19073-3269
Phone
(240) 780-6356
Employees
77, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Boston, Massachusetts

Stock & identifiers

Ticker
AVBP
Exchange
Nasdaq
IPO date
Jan 26, 2024
Shares outstanding
49M, Aug 10, 2026
Public float
$762.66M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1868279
CUSIP
04272N102
ISIN
US04272N1028
FIGI
BBG011N37VQ0
Share class FIGI
BBG011N37VW3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Stuart LutzkerPresident of R&D, Director147,744
Zhengbin YaoPresident and CEO, Director613,138
Robin LaChapelleChief Operating Officer570,906
Winston KungChief Financial Officer–
James Paul KastenmayerGeneral Counsel7,386
John HohnekerDirector–
Chris NoletDirector–
Kristine PetersonDirector–
Merdad ParseyDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Zhengbin (Bing) Yao, Ph.D
Chief Executive Officer and President
$596.67K$8.41M$358.00K$14.00K$9.37M+290%
Stuart Lutzker, M.D., Ph.D
President, Research and Development
$515.78K$2.65M$247.57K$14.00K$3.43M+248%
Winston Kung, MBA
Chief Financial Officer and Treasurer
$492.42K$2.65M$246.29K$14.00K$3.41M+86%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 26, 2024
Offer price
$18.00
Securities offered
9,722,222
Gross proceeds
$175.00M
Exchange
Nasdaq
First trading day
Jan 26, 2024
First-day close
$20.00+11.1%
Lock-up ends (est.)
Jul 24, 2024

“The initial public offering price is $18.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 77 employees, all of whom were full-time and 45 of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?